When evaluating opportunities for development in indications with expression of the TAT, we identified several scenarios not exploited like Enfortumab vedotin, anti‐Nectin4, in cervical and lung cancer, Tisotumab vedotin, anti‐TF, in glioblastoma and pancreatic cancer, or Sacituzumab govitecan, anti‐TROP2, in cervical, pancreatic, gastric, thyroid and endometrial cancer. This evidence concerns the gene TF and glioblastoma.